MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 558559 | Name: Moxaverine hydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Moxaverine hydrochloride is a derivative of papaverine, a phosphodiesterase inhibitor. Moxaverine has been studied in phase III of a clinical trial for the treatment of ocular blood flow in patients with age- related macular degeneration and primary open angle glaucoma.

Chemical Structure

Moxaverine hydrochloride
Moxaverine hydrochloride
CAS#1163-37-7

Theoretical Analysis

MedKoo Cat#: 558559

Name: Moxaverine hydrochloride

CAS#: 1163-37-7

Chemical Formula: C20H22ClNO2

Exact Mass: 343.1300

Molecular Weight: 343.85

Elemental Analysis: C, 69.86; H, 6.45; Cl, 10.31; N, 4.07; O, 9.31

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Moxaverine hydrochloride; Moxaverine HCl;
IUPAC/Chemical Name
1-Benzyl-3-ethyl-6,7-dimethoxyisoquinolinium chloride
InChi Key
DULZSDGCXSLVAQ-UHFFFAOYSA-N
InChi Code
InChI=1S/C20H21NO2.ClH/c1-4-16-11-15-12-19(22-2)20(23-3)13-17(15)18(21-16)10-14-8-6-5-7-9-14;/h5-9,11-13H,4,10H2,1-3H3;1H
SMILES Code
COC1=CC2=C(CC3=CC=CC=C3)[NH+]=C(CC)C=C2C=C1OC.[Cl-]
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.03.00
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 343.85 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Schmidl D, Pemp B, Lasta M, Boltz A, Kaya S, Palkovits S, Prager F, Schmetterer L, Garhofer G. Effects of orally administered moxaverine on ocular blood flow in healthy subjects. Graefes Arch Clin Exp Ophthalmol. 2013 Feb;251(2):515-20. doi: 10.1007/s00417-012-2207-1. Epub 2012 Dec 1. PubMed PMID: 23203292. 2: Becker U, Ehrhardt C, Schaefer UF, Gukasyan HJ, Kim KJ, Lee VH, Lehr CM. Tissue distribution of moxaverine-hydrochloride in the rabbit eye and plasma. J Ocul Pharmacol Ther. 2005 Jun;21(3):210-6. PubMed PMID: 15969638. 3: Pemp B, Garhofer G, Lasta M, Schmidl D, Wolzt M, Schmetterer L. The effects of moxaverine on ocular blood flow in patients with age-related macular degeneration or primary open angle glaucoma and in healthy control subjects. Acta Ophthalmol. 2012 Mar;90(2):139-45. doi: 10.1111/j.1755-3768.2010.01878.x. Epub 2010 Apr 23. PubMed PMID: 20456253. 4: Schmid-Schönbein H, Schröder S, Grebe R, Artmann G, Eschweiler H, Teitel P. Influence of moxaverine hydrochloride on membrane curvature and microsieve filterability of red cells after exposure to hyperosmolarity and lactacidosis. Arzneimittelforschung. 1988 May;38(5):710-6. PubMed PMID: 3415714. 5: Resch H, Weigert G, Karl K, Pemp B, Garhofer G, Schmetterer L. Effect of systemic moxaverine on ocular blood flow in humans. Acta Ophthalmol. 2009 Nov;87(7):731-5. doi: 10.1111/j.1755-3768.2008.01338.x. Epub 2008 Sep 5. PubMed PMID: 18778333. 6: Mannhold R. Inhibition of calmodulin dependent c-AMP-phosphodiesterase by moxaverine and papaverine. Arzneimittelforschung. 1988 Dec;38(12):1806-8. PubMed PMID: 2854468. 7: Leung E, Landa G. Update on current and future novel therapies for dry age-related macular degeneration. Expert Rev Clin Pharmacol. 2013 Sep;6(5):565-79. doi: 10.1586/17512433.2013.829645. Epub 2013 Aug 24. Review. PubMed PMID: 23971874. 8: Berg G, Andersson RG, Ryden G. Effects of different phosphodiesterase-inhibiting drugs on human pregnant myometrium: an in vitro study. Arch Int Pharmacodyn Ther. 1987 Dec;290(2):288-92. PubMed PMID: 3446047. 9: Chen R, Qi J, Mao Z, Cui S. Rh(iii)-catalyzed C-H activation/cyclization of oximes with alkenes for regioselective synthesis of isoquinolines. Org Biomol Chem. 2016 Jul 14;14(26):6201-4. doi: 10.1039/c6ob00942e. Epub 2016 Jun 8. PubMed PMID: 27273816. 10: Becker U, Ehrhardt C, Schneider M, Muys L, Gross D, Eschmann K, Schaefer UF, Lehr CM. A comparative evaluation of corneal epithelial cell cultures for assessing ocular permeability. Altern Lab Anim. 2008 Feb;36(1):33-44. PubMed PMID: 18333713. 11: Rogausch H. Influence of shape stabilizing agents on the deformability and morphology of lysolecithin-treated erythrocytes. Arzneimittelforschung. 1988 Oct;38(10):1478-81. PubMed PMID: 3196389. 12: Feine-Haake G. [Cerebrovascular disorders. Conservative therapy using Kollateral forte]. ZFA (Stuttgart). 1980 Mar;56(8):575-8. German. PubMed PMID: 7415502. 13: SINGER R. [Not Available]. Wien Klin Wochenschr. 1947 Aug 8;59(31):514-6. Undetermined Language. PubMed PMID: 20269779. 14: SCHROCKSNADEL H, WALTINGER K. [Not Available]. Z Kreislaufforsch. 1948 May;37(9-10):233-9. Undetermined Language. PubMed PMID: 18878734. 15: FERABOLI PC. [Treatment of peripheral vascular diseases with tocopheral and with eupaverin]. Gazz Med Ital. 1952 Nov;111(11):285-8. Undetermined Language. PubMed PMID: 13043798. 16: Girgis EH. Ion-pair reversed-phase liquid chromatographic identification and quantitation of papaverine congeners. J Pharm Sci. 1993 May;82(5):503-5. PubMed PMID: 8360827. 17: Bayer R, Plewa S, Borcescu E, Claus W. Filterability of human erythrocytes--drug induced prevention of aging in vitro. Arzneimittelforschung. 1988 Dec;38(12):1765-7. PubMed PMID: 3245847. 18: Haude M, Brennecke R, Erbel R, Jung D, Kiefer E, Schmidt T, Meyer J. The effect of balloon dilatation on post-stenotic myocardial perfusion before and after stimulation of coronary flow reserve: evaluation by the densitometric parameter 'mean rise time'. Int J Card Imaging. 1988;3(2-3):127-32. PubMed PMID: 3049844. 19: Lu Q, Greßies S, Cembellín S, Klauck FJR, Daniliuc CG, Glorius F. Redox-Neutral Manganese(I)-Catalyzed C-H Activation: Traceless Directing Group Enabled Regioselective Annulation. Angew Chem Int Ed Engl. 2017 Oct 2;56(41):12778-12782. doi: 10.1002/anie.201707396. Epub 2017 Sep 5. PubMed PMID: 28809458. 20: Gürtler U, Fuchs P, Stangelmayer A, Bernhardt G, Buschauer A, Spruss T. Construction and validation of a microprocessor controlled extracorporal circuit in rats for the optimization of isolated limb perfusion. Arch Pharm (Weinheim). 2004 Dec;337(12):672-81. PubMed PMID: 15597400.